GH-axis peptide narrative review
Various · Narrative review · 2026 · Review
Contrasts peer-reviewed PK/PD data with online self-dosing protocols and stratifies GHRH analogues by evidence quality.
GHRH analogue
A DPP-4-resistant GHRH analogue that stimulates GH/IGF-1.
At a glance
Overview
Synthetic analogue of GHRH(1-29) with four substitutions for protease resistance.
The "no-DAC" form is short-acting; the with-DAC form binds albumin for a multi-day half-life.
Mechanism
Activates pituitary GHRH receptors (Gs-coupled, cAMP/PKA) to drive GH secretion while preserving somatostatin feedback.
Research
Various · Narrative review · 2026 · Review
Contrasts peer-reviewed PK/PD data with online self-dosing protocols and stratifies GHRH analogues by evidence quality.
Teichman SL, et al. · J Clin Endocrinol Metab · 2006 · RCT
Single subcutaneous doses raised GH 2–10× for six-plus days in healthy adults; the key human study.
Alba M, et al. · Am J Physiol Endocrinol Metab · 2006 · Preclinical
Once-daily CJC-1295 normalised growth in GHRH-knockout mice.
Jetté L, et al. · Endocrinology · 2005 · Foundational
The design/discovery paper identifying CJC-1295 as a long-acting albumin-binding GRF analogue.
Sackmann-Sala L, et al. · Growth Hormone & IGF Research · 2009 · Human
Documents GH/IGF-1 axis activation and serum protein changes in normal adults.
Evidence summary
Supported by human studies showing sustained growth-hormone and IGF-1 elevation, built on an elegantly engineered, protease-resistant design. A well-founded GHRH analogue with a clear, reproducible mechanism and plenty of room for further exploration.